Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Scivision Biotech's operating assets for the quarter that ended in Dec. 2025 was NT$1,615.2 Mil. Scivision Biotech's operating liabilities for the quarter that ended in Dec. 2025 was NT$204.2 Mil. Scivision Biotech's Total Assets for the quarter that ended in Sep. 2025 was NT$2,609.9 Mil. Therefore, Scivision Biotech's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.54.
Scivision Biotech Scaled Net Operating Assets Related Terms
Scivision Biotech Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Scivision Biotech's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech Scaled Net Operating Assets Chart
TPE:1786 vs ISRG, BDX, MDLN: Scaled Net Operating Assets Comparison
For the Medical Instruments & Supplies subindustry, Scivision Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.54 mean?
Scivision Biotech (TPE:1786) has a Scaled Net Operating Assets of 0.54 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Scivision Biotech and its competitors.
Is Scivision Biotech's Scaled Net Operating Assets too high?
Scivision Biotech's current Scaled Net Operating Assets is 0.54. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's Scaled Net Operating Assets compare to ISRG and BDX?
Scivision Biotech's Scaled Net Operating Assets of 0.54 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Scivision Biotech and its competitors. Scivision Biotech's current Scaled Net Operating Assets is 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current Scaled Net Operating Assets is 0.54. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current Scaled Net Operating Assets is 0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23.
GuruFocus considers Scivision Biotech to be Possible Value Trap.
Key valuation signals for TPE:1786:
Scaled Net Operating Assets: 0.54
GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
80GF Score
Get the complete analysis for TPE:1786
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
